CDK5 Inhibitors for Neurodegeneration

📖 Wiki Page

therapeutic1136 wordssynced 2026-04-02

CDK5 Inhibitors for Neurodegeneration

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">CDK5 Inhibitors for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Category</td>
<td>Kinase Inhibitor</td>
</tr>
<tr>
<td class="label">Target</td>
<td>CDK5/p35, CDK5/p25</td>
</tr>
<tr>
<td class="label">Conditions</td>
<td>Alzheimer's Disease, Parkinson's Disease, ALS, Huntington's Disease</td>
</tr>
<tr>
<td class="label">Status</td>
<td>Preclinical/Research</td>
</tr>
<tr>
<td class="label">Type</td>
<td>ATP-competitive inhibitor</td>
</tr>
<tr>
<td class="label">CDK Targets</td>
<td>CDK5, CDK2, CDK7, CDK9</td>
</tr>
<tr>
<td class="label">IC50</td>
<td>0.2-0.5 μM for CDK5</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Multi-CDK inhibitor</td>
</tr>
<tr>
<td class="label">CDK Targets</td>
<td>CDK5, CDK2, CDK9, CDK1</td>
</tr>
<tr>
<td class="label">IC50</td>
<td>0.1 μM for CDK5</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Model</td>
</tr>
<tr>
<td class="label">Roscovitine</td>
<td>[APP](/entities/app-protein)/PS1 mice</td>
</tr>
<tr>
<td class="label">AT7519</td>
<td>3xTg-AD mice</td>
</tr>
<tr>
<td class="label">p25 siRNA</td>
<td>Mouse models</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Compound</td>
</tr>
<tr>
<td class="label">NCT00762723</td>
<td>Roscovitine</td>
</tr>

...

CDK5 Inhibitors for Neurodegeneration

Introduction

[Cdk5](/proteins/cdk5-protein) Inhibitors For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Cyclin-dependent kinase 5 (CDK5) is a serine/threonine kinase critical for neuronal development and function. Dysregulation of [CDK5](/proteins/cdk5-protein) activity contributes to neurodegenerative diseases through [tau](/proteins/tau) hyperphosphorylation, synaptic dysfunction, and neuronal [apoptosis](/entities/apoptosis). [CDK5](/genes/cdk5) inhibitors represent a promising therapeutic strategy. [@zheng2020]

Overview

Molecular Mechanisms

CDK5 Activation

CDK5 is activated by binding to neuronal-specific regulatory subunits:

p35: Normal activation, participates in synaptic plasticity
p25: Truncated form generated by calpain cleavage, pathological activation

Pathological Mechanisms

Tau Hyperphosphorylation

CDK5 phosphorylates tau at multiple AD-relevant sites:

Ser202: Early tau modification in NFTs
Thr231: conformational change, seeding
Ser396: Affects microtubule binding

Synaptic Dysfunction

CDK5/p25 contributes to:

AMPA receptor internalization: Impairs synaptic plasticity
Dendritic spine loss: Reduces synaptic connectivity
[LTP](/mechanisms/long-term-potentiation) impairment: Memory deficits

Apoptotic Pathways

CDK5/p25 promotes neuronal death through:

Mitochondrial dysfunction: Cytochrome c release
DNA damage: p53 activation
Caspase activation: Executioner caspase cleavage

Drug Candidates

Roscovitine (Seliciclib)

Clinical Development: Tested in ALS (Phase II) and cystic fibrosis. Shows neuroprotective effects in preclinical models.

Results: Mixed results in ALS trials; ongoing studies in AD.

AT7519

Preclinical Evidence: Reduced tau phosphorylation in AD models; protected dopaminergic [neurons](/entities/neurons) in PD models.

DRB (5,6-Dichloro-1-β-D-ribofuranosylbenzimidazole)

First-generation CDK inhibitor
Used primarily as research tool
Limited CNS penetration

Purvalanol A/B

CDK5/2 selective inhibitors
Reduced tau pathology in cell models
Not yet tested in vivo

Therapeutic Strategies

Direct CDK5 Inhibition

Small molecule inhibitors target the ATP-binding pocket:

Prevent p25 binding
Block substrate phosphorylation
Restore normal tau metabolism

p25 Expression Reduction

Calpain Inhibitors

Prevent p25 generation from p35
Reduce pathological CDK5 activity
Examples: Calpeptin, ALLM

Gene Therapy

siRNA against p25
CRISPR approaches
Viral vector delivery

Neuroprotective Downstream Effects

CDK5 inhibition provides:

Reduced tau phosphorylation
Improved synaptic function
Decreased apoptosis
Enhanced [autophagy](/entities/autophagy)

Clinical Evidence

Alzheimer's Disease

Parkinson's Disease

MPTP mice: Roscovitine protected dopaminergic neurons
[α-Synuclein](/proteins/alpha-synuclein) models: Reduced pathology
Human studies: No clinical trials completed

ALS

Note: CDK5 inhibitors have not yet shown efficacy in ALS clinical trials.

Huntington's Disease

Reduced mutant [huntingtin](/proteins/huntingtin-protein) toxicity
Improved motor function in mouse models
No clinical trials to date

Challenges and Limitations

Drug Delivery

[Blood-brain barrier](/entities/blood-brain-barrier) penetration: Limited for many compounds
Formulation: Need for CNS-targeted delivery
Stability: Metabolic stability concerns

Selectivity

Off-target effects: CDK family selectivity important
Toxicity: CDK2 inhibition causes hematological effects
Therapeutic window: Narrow margin

Clinical Translation

Species differences: Mouse to human translation challenging
Timing: Optimal intervention window unclear
Biomarkers: Need for patient selection markers

Combination Approaches

With Approved AD Drugs

With Other Kinase Inhibitors

[GSK-3β](/entities/gsk3-beta) inhibitors: Dual tau kinase inhibition
Lrrk2 inhibitors: Parkinson's disease combination
CDK5/2 selective: Broader neuroprotection

Research Directions

Novel Inhibitors

CNS-optimized compounds: Improved brain penetration
Allosteric inhibitors: Greater selectivity
PROTACs: Targeted protein degradation

Biomarkers

p-tau in CSF: Treatment response marker
[Neurofilament light](/biomarkers/neurofilament-light-chain-nfl): Disease progression
PET ligands: [Tau](/proteins/tau) imaging

Personalized Medicine

Genetic stratification: CDK5 pathway polymorphisms
Disease staging: Preclinical vs. clinical intervention
Combination optimization: Patient-specific regimens

Background

The study of Cdk5 Inhibitors For Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Cross-References

[Tau Pathology Pathway](/mechanisms/tau-pathology-pathway)
[GSK-3 Beta Pathway](/mechanisms/gsk3-beta-pathway)
[Alzheimer's Disease Treatments](/therapeutics/alzheimers-disease-treatments)
[Parkinson's Disease Treatments](/therapeutics/parkinsons-disease-treatments)
[Kinase Inhibitors](/therapeutics/kinase-inhibitors-neurodegeneration)

External Links

[CDK5 - Wikipedia](https://en.wikipedia.org/wiki/CDK5)
[CDK5 Inhibitors in Clinical Trials](https://clinicaltrials.gov/?term=CDK5+inhibitor+neurodegeneration)
[Nature Reviews - CDK5](https://www.nature.com/articles/nrm2635)

References

[Lau LF, et al, Targeting CDK5 in Alzheimer's disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35637447/)

[Zheng YL, et al, CDK5 as a therapeutic target in Alzheimer's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32651318/)

[Sun KH, et al, CDK5 inhibitors: a promising therapy for Alzheimer's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/34380567/)

[Shukla V, et al, Roscovitine analog, seliciclib, in neurodegenerative diseases (2020)](https://pubmed.ncbi.nlm.nih.gov/32027432/)

[Binukumar BK, et al, CDK5: A unique target for Alzheimer's disease therapy (2021)](https://pubmed.ncbi.nlm.nih.gov/33862345/)

[Zhang M, et al, AT7519, a CDK inhibitor, attenuates tau pathology in Alzheimer's disease models (2022)](https://pubmed.ncbi.nlm.nih.gov/35030492/)

[Piedrahita D, et al, CDK5-mediated phosphorylation of neuronal proteins in neurodegenerative diseases (2020)](https://pubmed.ncbi.nlm.nih.gov/32598547/)

[Liu SL, et al, The role of CDK5 in neurological disorders (2022)](https://pubmed.ncbi.nlm.nih.gov/35250481/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — 0.79 · Target: SIRT1
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — 0.79 · Target: CYP46A1
[Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — 0.77 · Target: HCRTR1/HCRTR2
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — 0.77 · Target: SMPD1
[Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — 0.76 · Target: ABCA1/LDLR/SREBF2
[Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — 0.76 · Target: NLRP3, CASP1, IL1B, PYCARD
[Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — 0.75 · Target: TFRC
[Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — 0.74 · Target: P2RY1 and P2RX7

Related Analyses:

[Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) 🔄
[Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) 🔄
[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄

📖 View canonical wiki page →

CDK5 Inhibitors for Neurodegeneration

CDK5 Inhibitors for Neurodegeneration

Introduction

CDK5 Inhibitors for Neurodegeneration

Introduction

Overview

Molecular Mechanisms

CDK5 Activation

Pathological Mechanisms

Tau Hyperphosphorylation

Synaptic Dysfunction

Apoptotic Pathways

Drug Candidates

Roscovitine (Seliciclib)

AT7519

DRB (5,6-Dichloro-1-β-D-ribofuranosylbenzimidazole)

Purvalanol A/B

Therapeutic Strategies

Direct CDK5 Inhibition

p25 Expression Reduction

Calpain Inhibitors

Gene Therapy

Neuroprotective Downstream Effects

Clinical Evidence

Alzheimer's Disease

Parkinson's Disease

ALS

Huntington's Disease

Challenges and Limitations

Drug Delivery

Selectivity

Clinical Translation

Combination Approaches

With Approved AD Drugs

With Other Kinase Inhibitors

Research Directions

Novel Inhibitors

Biomarkers

Personalized Medicine

Background

Cross-References

See Also

External Links

References

Related Hypotheses